Wednesday, July 22, 2026 The Q2 2026 quarterly update for pending CCTG trials with approximate activation timelines are listed below. For more information between the quarterly updates, find the most recent updates and stories of recently opened CCTG trials here: https://www.ctg.queensu.ca/public/trials-development.ALC11 (HEMATOLOGIC) – Expected: Q4 2026Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH SubstudyALC9 (HEMATOLOGIC) – Expected: Q4 2026Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)BI4 (GASTROINTESTINAL) – Expected: Q3 2027Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)BR39 (LUNG) – Expected: Q4 2026LUNA-2: LND101 in Unresectable Non-small Cell Lung Cancer: A Randomized Phase II TrialEN12 (GYNECOLOGY) – Expected Q3 2026(RAINBO-ORANGE) Treatment of Endometrial Cancer Based on Molecular FeaturesHN14 (HEAD & NECK) – Expected: Q3 2026Delayed Reduced Volume and Dose Elective Radiotherepy (REVERT) in Patients with HNSCCMA42 (BREAST) – Expected: Q3 2026No Chemotherapy in Intermediate-risk HR + HER2 – Early Breast Cancer Treated with Ribociclib (NoLEEta)MD1 (HEMATOLOGIC) – Expected: Q3 2026Combination Therapy with Luspatercept in Lower Risk Myelodysplasia: A Tier 1 myeloMATCH SubstudyME18 (MELANOMA) – Expected: Q3 2027Selective Index Node Resection vs Lymph Node Dissection after Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma The Multicentre Selective Lymphadenectomy Trial-3 (MSLT-3)SR8 (SARCOMA) – Expected: Q2 2027A phase III study of hypofractionated alternative radiation with modulation of neoadjuvant/peri-operative immunotherapy in sarcoma (HARMONY)IND241E (METASTATIC BREAST CANCER) – Expected: Q3 2026A phase II study of CFI-402257 in patients with CDK4/6 inhibitor treated ER+/HER2- metastatic breast cancerIND241F (METASTATIC BREAST CANCER) – Expected: Q3 2026A phase II study of CFI-400945 in patients with CDK4/6 inhibitor treated ER+/HER2- metastatic breast cancerOpened Q2 2026IND246 (SELECTED SOLID TUMORS) (GCAR1) A chimeric antigen receptor (CAR) t-cell therapy in selected relapsed/refractory GPNMB-expressing alveolar soft-part sarcoma, renal cell carcinoma, and triple negative breast cancerIND245 (MANTLE CELL LYMPHOMA) Sonrotoclax and Zanubrutinib in patients with relapsed/refractory mantle cell lymphoma receiving standard of care CAR-t cell therapyIND241G (METASTATIC BREAST CANCER)A phase II study of sacituzumab govitecan in patients with CDK4/6 inhibitor treated ER+/HER2- metastatic breast cancerALC10 (HEMATOLOGIC)Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment TrialLYC2 (LYMPHOMA)Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)PAC5 (GASTROINTESTINAL)Lanreotide for the Prevention of Postoperative Pancreatic FistulaSC31 (SUPPORTIVE CARE)Using SMART to optimize the stepped care delivery of TEMPO – a Tailored, dyadic, wEb-based physical activity and self-Management Program for men with prostate cancer and their caregivers (TEMPO)
